Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes
Authors:
- 7 February 2008
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 15 (7) , 516-523
Abstract
Mitochondrial diseases are not uncommon, and may result from mutations in both nuclear and mitochondrial DNA (mtDNA). At present, only palliative therapies are available for these disorders, and interest in the development of efficient treatment protocols is high. Here, we demonstrate that in cells heteroplasmic for the T8993G mutation, which is a cause for the NARP and MILS syndromes, infection with an adenovirus, which encodes the mitochondrially targeted R.XmaI restriction endonuclease, leads to selective destruction of mutant mtDNA. This destruction proceeds in a time- and dose-dependent manner and results in cells with significantly increased rates of oxygen consumption and ATP production. The delivery of R.XmaI to mitochondria is accompanied by improvement in the ability to utilize galactose as the sole carbon source, which is a surrogate indicator of the proficiency of oxidative phosphorylation. Concurrently, the rate of lactic acid production by these cells, which is a marker of mitochondrial dysfunction, decreases. We further demonstrate that levels of phosphorylated P53 and γH2ax proteins, markers of nuclear DNA damage, do not change in response to infection with recombinant adenovirus indicating the absence of nuclear DNA damage and the relative safety of the technique. Finally, some advantages and limitations of the proposed approach are discussed.Keywords
This publication has 36 references indexed in Scilit:
- Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylaseProceedings of the National Academy of Sciences, 2006
- A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary MedicineAnnual Review of Genetics, 2005
- An Adenovirus Type 5 (Ad5) Amplicon-Based Packaging Cell Line for Production of High-Capacity Helper-Independent ΔE1-E2-E3-E4 Ad5 VectorsJournal of Virology, 2005
- Mitochondrial DNA mutations in human diseaseNature Reviews Genetics, 2005
- Gene Therapy for Mitochondrial Disease by Delivering Restriction Endonuclease SmaI into MitochondriaJournal of Biomedical Science, 2002
- Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonucleaseHuman Molecular Genetics, 2001
- The inheritance of mitochondrial DNA heteroplasmy: random drift, selection or both?Trends in Genetics, 2000
- Genetic Counseling and Prenatal Diagnosis for the Mitochondrial DNA Mutations at Nucleotide 8993The American Journal of Human Genetics, 1999
- Limitations to in vivo Import of Hydrophobic Proteins into Yeast MitochondriaEuropean Journal of Biochemistry, 1995
- Nonviability of cells with oxidative defects in galactose medium: A screening test for affected patient fibroblastsBiochemical Medicine and Metabolic Biology, 1992